RESUMO
BACKGROUND: Bronchioloalveolar carcinoma (BAC) is a histological subtype of non-small cell lung cancer (NSCLC), particularly of adenocarcinoma. Given its multifocality and the poor activity of chemotherapy, there is no established treatment for BAC, although promising results have been achieved with inhibitors of the epidermal growth factor receptor (EGFR). No tumor marker has been validated in the diagnosis and follow-up of lung cancer, in particular to predict the outcome of treatment with EGFR inhibitors. PURPOSE: As CA 15-3 antigen serum levels are reported to be pathologically abnormal in adenocarcinoma of the lung, we chose this tumor marker to monitor treatment with EGFR inhibitors of patients affected by adenocarcinoma with BAC features or pure BAC. PATIENTS AND METHODS: We collected data from 26 consecutive Caucasian patients with BAC, mostly women and never smokers, who received EGFR inhibitors. RESULTS: We noticed that all patients with normal CA 15-3 serum levels at baseline (15/26, 57.7%) showed a response to EGFR inhibitors, whereas all patients with abnormal CA 15-3 serum levels (11/26, 42.3%) did not. CONCLUSION: Our data suggest that CA 15-3 levels might be a predictive factor for the response to EGFR inhibitors in patients with BAC.
Assuntos
Adenocarcinoma Bronquioloalveolar/tratamento farmacológico , Adenocarcinoma Bronquioloalveolar/metabolismo , Biomarcadores Tumorais , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Receptores ErbB/antagonistas & inibidores , Regulação Neoplásica da Expressão Gênica , Neoplasias Pulmonares/metabolismo , Mucina-1/biossíntese , Mucina-1/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Feminino , Predisposição Genética para Doença , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Pessoa de Meia-IdadeRESUMO
The mitotic cell cycle is a tightly regulated process that ensures the correct division of one cell into two daughter cells. Progress along the different phases of the cell cycle is positively regulated by the sequential activation of a family of serine-threonine kinases called CDKs (Cyclin Dependent Kinases). Their activity is counteracted by small proteins known as CDK inhibitors (CKI) that ensure the correct timing of CDK activation in the different phases of the cell cycle. The present review will deal with the role of one of this CKI, p27(kip1), in human cancer, focusing in particular on the mechanisms underlying its functional inactivation in tumor cells. p27(kip1) protein downregulation is usually achieved by proteasomal degradation and is often correlated to a worse prognosis in several types of human cancers, resulting in the reduction of disease free and overall survival. More recently, it has been proposed that p27(kip1) protein, rather than degraded, can be functionally inactivated. The mechanisms and the implications of these two types of p27(kip1) deregulation will be discussed and some potential therapeutic approaches targeting p27(kip1) functions will be proposed.
Assuntos
Proteínas de Ciclo Celular/fisiologia , Ciclo Celular/fisiologia , Neoplasias/patologia , Proteínas Supressoras de Tumor/fisiologia , Animais , Proteínas de Ciclo Celular/antagonistas & inibidores , Proteínas de Ciclo Celular/genética , Proteínas de Ciclo Celular/metabolismo , Divisão Celular/fisiologia , Inibidor de Quinase Dependente de Ciclina p27 , Quinases Ciclina-Dependentes/antagonistas & inibidores , Quinases Ciclina-Dependentes/metabolismo , Regulação Neoplásica da Expressão Gênica , Inativação Gênica , Terapia Genética/métodos , Humanos , Neoplasias/tratamento farmacológico , Neoplasias/metabolismo , Proteínas Supressoras de Tumor/antagonistas & inibidores , Proteínas Supressoras de Tumor/genética , Proteínas Supressoras de Tumor/metabolismoRESUMO
Referente a un proceso destinado a eliminar el acido ellagico y sus complejos organometalicos del efluente producido al tratar maderas que contienen taninos ellagicos. El Centro de Investigación de Celulosa y Papel desarrollo un método que permite el tratamiento de estos efluentes por el cual se obtiene un licor a partir del cual se pueden recuperar los subproductos
Assuntos
Efluentes Industriais , Indústria de Papel e Celulose , ÁcidosRESUMO
Referente a un proceso destinado a eliminar el acido ellagico y sus complejos organometalicos del efluente producido al tratar maderas que contienen taninos ellagicos. El Centro de Investigación de Celulosa y Papel desarrollo un método que permite el tratamiento de estos efluentes por el cual se obtiene un licor a partir del cual se pueden recuperar los subproductos
Assuntos
Efluentes Industriais , Indústria de Papel e Celulose , ÁcidosRESUMO
Propone el método de adsorción selectiva para eliminar el ácido ellágico del licor residual. Este método ha demostrado, en el transcurso de las pruebas de laboratorio, cumplir con los requisitos necesarios para su aplicación a escala industrial
Assuntos
Efluentes Industriais , Ácidos , Indústria de Papel e CeluloseRESUMO
Propone el método de adsorción selectiva para eliminar el ácido ellágico del licor residual. Este método ha demostrado, en el transcurso de las pruebas de laboratorio, cumplir con los requisitos necesarios para su aplicación a escala industrial